Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INOmax in Pediatric Acute Hypoxemic Respiratory Failure
NCT00041561Phase 3Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jan 2002
- Primary completion
- Dec 2004
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 3 trial of nitric oxide in acute hypoxemic respiratory failure (AHRF), sponsored by Mallinckrodt Pharmaceuticals. Started Jan 2002; status: terminated.
02
Drugs
nitric oxide
03
Conditions
acute hypoxemic respiratory failure (AHRF)
Beyond the preview
Go deeper on NCT00041561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041561.